To Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity using Ultrasound, GE HealthCare and Novo Nordisk will Work Together

Peripheral focused ultrasound (PFUS) product development will advance thanks to a partnership between GE HealthCare and Novo Nordisk. With the help of ultrasound, this cutting-edge technology may be able to precisely control metabolic activity in the body, supporting the treatment of long-term conditions including type 2 diabetes and obesity.

Using ultrasound to trigger the nervous system and perhaps treat disease, PFUS is a non-invasive kind of bioelectronic therapy. Personalized ultrasonic stimulation of neural pathways may have an effect on glucose metabolism in persons with diabetes, according to preliminary early-stage clinical studies and pre-clinical proof of concept. If supported by additional clinical proof, PFUS might be a non-pharmacologic method of bringing blood sugar levels back to normal.